Chondroitin sulfate prevents peritoneal fibrosis in mice by suppressing NF-κB activation
Authors:
- 15 February 2016
- journal article
- research article
- Published by Springer Nature in Medical Molecular Morphology
- Vol. 49 (3) , 144-153
Abstract
Long-term peritoneal dialysis causes peritoneal fibrosis, and previous reports suggest that inflammation plays a critical role in peritoneal fibrosis. Chondroitin sulfate (CS) suppresses the inflammatory response by preventing activation of nuclear factor (NF)-κB. We examined the effect of CS on the peritoneal fibrosis induced by chlorhexidine gluconate (CG) in mice. CS or water was administered daily. We divided mice into four groups: administered vehicle and water (control); administered vehicle and CS (CS); administered CG and water (CG); and administered CG and CS (CG+CS). Morphologic changes were assessed by Masson’s trichrome staining. Inflammation- and fibrosis-associated factors were assessed by immunohistochemistry. Activation of NF-κB was examined by southwestern histochemistry. CS administration suppressed the progression of submesothelial thickening. The numbers of inflammation- and fibrosis-associated factors -positive cells were significantly decreased in the CG+CS group, compared to the CG group. Based on SWH, the CG+CS group contained significantly fewer NF-κB-activated cells than the CG group. Our results indicate that CS suppresses peritoneal fibrosis via suppression of NF-κB activation. These results suggest that CS has therapeutic potential for peritoneal fibrosis.Keywords
Funding Information
- The Japanese Association of Dialysis Physicians (25067)
This publication has 30 references indexed in Scilit:
- Peritonitis is still an important factor for withdrawal from peritoneal dialysis therapy in the Tokai area of JapanClinical and Experimental Nephrology, 2011
- Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRIAnnals of the Rheumatic Diseases, 2011
- The Pathophysiology of the Peritoneal MembraneJournal of the American Society of Nephrology, 2010
- Immunomodulatory and anti‐inflammatory effects of chondroitin sulphateJournal of Cellular and Molecular Medicine, 2009
- Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritisBritish Journal of Pharmacology, 2008
- Impact of Uremia, Diabetes, and Peritoneal Dialysis Itself on the Pathogenesis of Peritoneal SclerosisClinical Journal of the American Society of Nephrology, 2008
- Detection of nuclear factor-κB in IgA nephropathy using Southwestern histochemistryAmerican Journal of Kidney Diseases, 2003
- Codelivery of NF-κB Decoy-Related Oligodeoxynucleotide Improves LPD-Mediated Systemic Gene TransferMolecular Therapy, 2002
- Localization of cyclic adenosine 3',5'-monophosphate-responsive element (CRE)-binding proteins by southwestern histochemistry.Journal of Histochemistry & Cytochemistry, 1994
- Function and Activation of NF-kappaB in the Immune SystemAnnual Review of Immunology, 1994